Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Benign Prostatic Hyperplasia (BPH)
NCT04032067Phase 3Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tertomotide in benign prostatic hyperplasia (BPH), sponsored by GemVax & KAEL Co., Ltd.. Started Oct 2019; status: completed.
02
Drugs
tertomotide
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04032067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032067.